Rate My Professor Sherry Wu

Wu's research focuses on developing strategies to overcome immune suppression in ovarian and breast cancers, novel nanoparticle platforms for tumor-targeted delivery, and approaches to enhance patient survival. Key themes include understanding factors contributing to immune suppression, developing clinically translatable nanosystems to break immune barriers, and harnessing exosomes for non-coding RNA delivery. She has received major awards and fellowships such as the National Institutes of Health R35 Maximizing Investigators’ Research Award (2017-2018 and 2017-2024), Ovarian Cancer Research Fund Alliance Liz Tilberis Early Career Award (2016-2019), Cancer Institute NSW Career Development Fellowship (2018-2020, declined), Australian Ovarian Cancer Research Foundation grant (2017-2018), and NHMRC Postgraduate Scholarship (2006-2009). UQ Foundation Research Excellence Award in 2018. Notable publications include 'A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer' (Nature Communications, 2016), 'Hematogenous metastasis of ovarian cancer: rethinking mode of spread' (Cancer Cell, 2014), 'miR-146a inhibits ovarian tumor growth in vivo via targeting immunosuppressive neutrophils' (Molecular Therapy - Oncolytics, 2023), and '2’-OMe-phosphorodithioate modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity' (Nature Communications, 2014). Wu supervises PhD students on projects involving single-cell transcriptomics, AI for immunotherapy, exosome targeting, and nano-systems for cancer treatment.